Table 1.
Study, patient and treatment characteristics*
| Study | Number of patients | Blinding | Analyses | Trial duration (weeks) |
Setting (%) | Diagnosis (%) | Diagnostic criteria | Illness duration* (months) | Age*: years (range) | Sex*: male (%) | Control group: dose (mg/day): mean (range) | Intervention group: dose (mg/day): mean (range) |
Jadad score | Prolactin level at baseline (ng/mL) | |
| Chen et al 2009 (China)20 | T: 80 C: 40 I: 40 |
DB | OC | 8† | Inpatients (100) | Sz (100), first episode | CCMD-3 | 4.5 | 30.5 (18–48) | 100 | RIS: Ø=4.0 (2–5) |
RIS: Ø=4.1 (2–5) |
ARI: Ø=5 (FD) |
4 | 20.52 |
| Chen et al 2012 (China)21 | T: 86‡ C: 46 I: 40 |
OL | OC | 8§ | Inpatients (100) | Sz (100), first episode | CCMD-3 | NR | NR (18–55) |
0 | OLA: Ø=NR (5–20) |
OLA: Ø=NR (5–20) |
ARI: Ø=10 (FD) |
1 | 13.88 |
| Ren and Hu 2011 (China)22 | T: 72 C: 36 I: 36 |
SB¶ | ITT | 8 | Outpatients (0) | Sz (100), first episode | ICD-10 | NR | NR (18–60) |
NR | SUL: Ø=NR (400–900) |
SUL: Ø=NR (400–900) |
ARI: Ø=NR (NR) |
3 | 15.00 |
| Sha et al 2017 (China)23 | T: 62 C: 31 I: 31 |
OL | ITT | 8 | NR | Sz (100), first episode | CCMD | 26.0 | 42.9 (20–55) | 100 | AMI: Ø=NR (200–800) |
AMI: Ø=NR (200–800) |
ARI: Ø=2.5 (FD) |
3 | 12.69 |
| Zhou et al 2014 (China)24 | T: 100 C: 50 I: 50 |
OL | ITT | 24 | Both (NR) | Sz (100), first episode | CCMD-3 | NR | NR (18–40) |
0 | RIS: Ø=NR (4–6) |
RIS: Ø=NR (4–6) |
ARI: Ø=5 (FD) |
2 | 10.56 |
*Available data were extracted based on mean baseline value of each included trials.
†Only data receiving aripiprazole treatment were extracted.
‡Number of patients were the data from the completion of the trial because the random assignment data were not clear.
§Data were obtained by contacting with the first author.
¶Only used the placebo but it is unclear about the blinding of the rater.
Ø, mean; AMI, amisulpride; ARI, aripiprazole; Both, in–outpatients; C, control; CCMD, China's mental disorder classification and diagnosis standard; CCMD-3, China's mental disorder classification and diagnosis standard 3rd edition; DB, double blind; FD, fixed dose; I, intervention; ICD-10, the 10th revision of the International Statistical Classification of Diseases and Related Health Problems; ITT, intent to treat; NR, not reported; OC, observed cases; OL, open label; OLA, olanzapine; RIS, risperidone; SB, single blind; SUL, sulpiride; Sz, schizophrenia; T, total.